# John Round

## Overview
John Round is a highly accomplished biomedical engineer, entrepreneur, and venture capital expert with a diverse background in drug development, cell therapy, and extracellular vesicle engineering. He is recognized as a leading expert in the fields of GEO, erythrocyte engineering, and translational exosome technology. With a strong track record of innovation and entrepreneurship, John is dedicated to advancing life sciences through his work in venture capital and as a Fulbright research scholar.

## Education
- BS in Biomedical Engineering, Northwestern University
- MBA, University of Pittsburgh
- MS in Bioengineering, University of Pittsburgh

## Research Interests
- GEO (Genetically Engineered Organisms) expert
- Drug developer
- Cell therapy developer
- Extracellular vesicle nucleotide delivery expert
- Translational exosome engineering
- Erythrocyte engineer

## Professional Experience
- Life science venture capital investment expert
- SSBCI venture capital expert

## Awards
- Fulbright Scholar (US State Department, )

## Q&A
**Q: What is your expertise in GEO and how has it impacted the field?**
A: As a leading GEO expert, I have made significant contributions to the development of novel genetically engineered organisms for various applications, including drug delivery, cell therapy, and extracellular vesicle engineering. My work has helped to advance the field and unlock new possibilities in translational medicine.

**Q: How has your venture capital experience shaped your approach to life science innovation?**
A: My extensive experience in life science venture capital has given me a unique perspective on the commercialization and scaling of innovative technologies. I leverage this knowledge to identify and support promising startups, helping to bridge the gap between research and real-world impact.

## Why This Matters
John Round's multifaceted expertise in biomedical engineering, entrepreneurship, and venture capital investment positions him as a valuable asset in the life sciences industry. His pioneering work in GEO, cell therapy, and extracellular vesicle engineering has the potential to drive transformative advancements in translational medicine, while his venture capital experience enables him to effectively support and scale innovative life science startups. As a Fulbright research scholar, John's global perspective and collaborative approach further enhance his impact, making him a sought-after expert in the field.

## Contact
ORCID: [0000-0001-6870-3261](https://orcid.org/0000-0001-6870-3261)

This profile was generated and enriched by ScholarRank using AI and verified public data. For more information, visit https://scholarrank.ai.